As Acquity, Synapt Sales Help Waters Post 13 Percent Q4 Growth, Firm Misses Forecast | GenomeWeb
A 20-plus-percent jump in sales of its Acquity UPLC, Synapt High Definition mass spectrometry, and TA instruments helped Waters post a 13-percent rise in total fourth-quarter sales, though the results missed company expectations.
The quarter was marked by “mixed results” from Waters’ largest pharma clients, where “a minority of firms depress[ed] the sales growth of the group as a whole,” according to CEO Douglas Berthiaume.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.